Clinical management of HIV drug resistance

KJ Cortez, F Maldarelli - Viruses, 2011 - mdpi.com
Combination antiretroviral therapy for HIV-1 infection has resulted in profound reductions in
viremia and is associated with marked improvements in morbidity and mortality. Therapy is …

Minority variants of drug-resistant HIV

S Gianella, DD Richman - The Journal of infectious diseases, 2010 - academic.oup.com
Minor drug-resistant variants exist in every patient infected with human immunodeficiency
virus (HIV). Because these minority variants are usually present at very low levels, they …

Low-abundance HIV drug-resistant viral variants in treatment-experienced persons correlate with historical antiretroviral use

T Le, J Chiarella, BB Simen, B Hanczaruk, M Egholm… - PloS one, 2009 - journals.plos.org
Background It is largely unknown how frequently low-abundance HIV drug-resistant variants
at levels under limit of detection of conventional genotyping (< 20% of quasi-species) are …

Sensitive deep-sequencing-based HIV-1 genotyping assay to simultaneously determine susceptibility to protease, reverse transcriptase, integrase, and maturation …

RM Gibson, AM Meyer, D Winner, J Archer… - Antimicrobial agents …, 2014 - Am Soc Microbiol
With 29 individual antiretroviral drugs available from six classes that are approved for the
treatment of HIV-1 infection, a combination of different phenotypic and genotypic tests is …

Attenuators

JM Yeakley, B Seligmann, J McComb - US Patent 9,957,550, 2018 - Google Patents
US9957550B2 - Attenuators - Google Patents US9957550B2 - Attenuators - Google Patents
Attenuators Download PDF Info Publication number US9957550B2 US9957550B2 US14/480,525 …

HIV-1 resistance to maraviroc conferred by a CD4 binding site mutation in the envelope glycoprotein gp120

AN Ratcliff, W Shi, EJ Arts - Journal of virology, 2013 - Am Soc Microbiol
Maraviroc (MVC) is a CCR5 antagonist that inhibits HIV-1 entry by binding to the coreceptor
and inducing structural alterations in the extracellular loops. In this study, we isolated MVC …

Presence, persistence and effects of pre-treatment HIV-1 drug resistance variants detected using next generation sequencing: A Retrospective longitudinal study from …

AS Hassan, DF Bibby, SM Mwaringa, CA Agutu… - PloS one, 2019 - journals.plos.org
Background The epidemiology of HIV-1 drug resistance (HIVDR) determined by Sanger
capillary sequencing, has been widely studied. However, much less is known about HIVDR …

Divergent evolution in reverse transcriptase (RT) of HIV-1 group O and M lineages: impact on structure, fitness, and sensitivity to nonnucleoside RT inhibitors

DM Tebit, M Lobritz, M Lalonde, T Immonen… - Journal of …, 2010 - Am Soc Microbiol
Natural evolution in primate lentiviral reverse transcriptase (RT) appears to have been
constrained by the necessity to maintain function within an asymmetric protein composed of …

Transmitted HIV resistance to first-line antiretroviral therapy in Lima, Peru

J Soria, M Bull, C Mitchell, A La Rosa… - AIDS research and …, 2012 - liebertpub.com
Transmission of drug-resistant HIV (TDR) has been associated with virologic failure of “first-
line,” nonnucleoside reverse transcriptase inhibitor (NNRTI)-based antiretroviral therapy …

Covering all bases in HIV research: unveiling a hidden world of viral evolution.

B Vrancken, S Lequime, K Theys, P Lemey - AIDS reviews, 2010 - europepmc.org
The advent of next-generation sequencing technologies has greatly impacted genomic
research by providing a means for increasing the amount of sequence information in a cost …